Stock LALPATHLAB DR. LAL PATHLABS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Dr. Lal PathLabs Limited

Equities

LALPATHLAB

INE600L01024

Market Closed - NSE India S.E.
Other stock markets
 07:43:53 2024-05-31 am EDT 		5-day change 1st Jan Change
2,648 INR +0.78% Intraday chart for Dr. Lal PathLabs Limited +0.82% +2.72%
May. 14 Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505 MT
May. 10 Transcript : Dr. Lal PathLabs Limited, Q4 2024 Earnings Call, May 10, 2024

Evolution of the average Target Price on Dr. Lal PathLabs Limited

Price target over the last 5 years

History of analyst recommendation changes

ef2c4dd4ac30cb95da5ea5e.1qrky0f2iT95IJHBXZvtLQ3BNcp9a44zpim56IcYR9g.gc-eqnGsywsuc_itG9HUYV_wdqM3LvtxwXvqo8BBAoK77I6zLKD-b0pDoQ~7e036e694b65118e6ef71f6efd94bbcc

Analyst Recommendations on Dr. Lal PathLabs Limited

Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505 MT
Nomura Adjusts Dr. Lal Pathlabs’ Price Target to INR2,505 From INR2,465, Keeps at Neutral MT
Nomura Upgrades Dr. Lal Pathlabs to Neutral From Reduce, Adjusts Price Target to INR2,465 From INR,2002 MT
Nomura Downgrades Dr. Lal Pathlabs to Reduce From Neutral, Adjusts Price Target to INR2,002 From INR1,835 MT
Nomura Adjusts Dr. Lal PathLabs' Price Target to INR1,835 From INR1,864, Keeps at Neutral MT
Nomura Upgrades Dr. Lal PathLabs to Neutral From Reduce, Adjusts Price Target to INR1,864 From INR1,819 MT
CARE Assigns AA Rating on Dr. Lal Pathlabs' Long-term Bank Financing; Outlook Stable MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
2,648 INR
Average target price
2,489 INR
Spread / Average Target
-6.00%
High Price Target
2,900 INR
Spread / Highest target
+9.52%
Low Price Target
1,670 INR
Spread / Lowest Target
-36.93%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Dr. Lal PathLabs Limited

Nomura
Jefferies & Co.

Ratings for Dr. Lal PathLabs Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LALPATHLAB Stock
  4. Consensus Dr. Lal PathLabs Limited